Article
Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.
European journal of clinical pharmacology - 1 Sept 2015
Togashi Masaru, Niioka Takenori, Komatsuda Atsushi, Nara Mizuho, Okuyama Shin, Omokawa Ayumi, Abumiya Maiko, Wakui Hideki, Takahashi Naoto, Miura Masatomo
Abstract excerpt
PURPOSE: The aim of this study was to investigate the effect of itraconazole (ITCZ), a potent inhibitor of CYP3A4 and P-glycoprotein, on the blood concentration 12 h after tacrolimus administration (C 12h) in relation to CYP3A5 6986A>G and ABCB1 3435C>T genotype status in patients with connective tissue disease (CTD). METHODS: Eighty-one CTD patients taking tacrolimus (Prograf®) once daily at night (2100 hours)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
